Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Elelgrupi | Pharma | 24.1% | 65th pct | 110 |
| Pip Company | Pharma | -15.5% | 3rd pct | 110 |
| Grasse Pharma Georgia | Pharma | — | no FY data | 110 |
| Sando Pharma | Pharma | — | no FY data | 110 |
| Medimex | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 5 peers filed FY2024. Switch to FY2023 (3 of 5).
| Line item | Elelgrupi | Pip Company | Grasse Pharma Georgia | Sando Pharma | Medimex |
|---|---|---|---|---|---|
| Total Current Assets | 121 | 3,360 | — | — | — |
| Total Non-Current Assets | 1,868 | 3 | — | — | — |
| TOTAL ASSETS | 1,989 | 3,363 | — | — | — |
| Total Current Liabilities | 431 | 4,920 | — | — | — |
| Total Non-Current Liabilities | 200 | 30 | — | — | — |
| TOTAL LIABILITIES | 631 | 4,950 | — | — | — |
| Total Equity | 1,358 | -1,587 | — | — | — |
| Balance Check (Assets - L&E) | 0 | 0 | — | — | — |
| Total Debt | 0 | 0 | — | — | — |
| Cash & Equivalents | 169 | 3 | — | — | — |
| Net Debt | -169 | -3 | — | — | — |
Not every picked company reports every selected year — FY2024: 3 of 5 companies have no filing. Those cells are left blank (no filing), not zero.